Texture-based markers from structural imaging correlate with motor handicap in Parkinson's disease.
Aged
Antiparkinson Agents
/ adverse effects
Biomarkers
Brain
/ diagnostic imaging
Dyskinesia, Drug-Induced
/ diagnostic imaging
Female
Gray Matter
/ diagnostic imaging
Humans
Image Processing, Computer-Assisted
Levodopa
/ adverse effects
Magnetic Resonance Imaging
Male
Middle Aged
Nerve Degeneration
/ diagnostic imaging
Parkinson Disease
/ diagnostic imaging
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
received:
04
09
2020
accepted:
28
12
2020
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
12
11
2021
Statut:
epublish
Résumé
There is a growing need for surrogate biomarkers for Parkinson's disease (PD). Structural analysis using magnetic resonance imaging with T1-weighted sequences has the potential to quantify histopathological changes. Degeneration is typically measured by the volume and shape of morphological changes. However, these changes appear late in the disease, preventing their use as surrogate markers. We investigated texture changes in 108 individuals, divided into three groups, matched in terms of sex and age: (1) healthy controls (n = 32); (2) patients with early-stage PD (n = 39); and (3) patients with late-stage PD and severe L-dopa-related complications (n = 37). All patients were assessed in off-treatment conditions. Statistical analysis of first- and second-order texture features was conducted in the substantia nigra, striatum, thalamus and sub-thalamic nucleus. Regions of interest volumetry and voxel-based morphometry were performed for comparison. Significantly different texture features were observed between the three populations, with some showing a gradual linear progression between the groups. The volumetric changes in the two PD patient groups were not significantly different. Texture features were significantly associated with clinical scores for motor handicap. These results suggest that texture features, measured in the nigrostriatal pathway at PD diagnosis, may be useful in predicting clinical progression of motor handicap.
Identifiants
pubmed: 33526820
doi: 10.1038/s41598-021-81209-4
pii: 10.1038/s41598-021-81209-4
pmc: PMC7851138
doi:
Substances chimiques
Antiparkinson Agents
0
Biomarkers
0
Levodopa
46627O600J
Banques de données
ClinicalTrials.gov
['NCT02360683']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2724Références
Neuroimage. 2000 Jun;11(6 Pt 1):805-21
pubmed: 10860804
Neuroimage. 2012 Jan 16;59(2):1315-23
pubmed: 21889995
Brain. 2013 Aug;136(Pt 8):2419-31
pubmed: 23884810
Neurochem Int. 2017 Mar;104:34-48
pubmed: 28082232
Mov Disord. 2012 Jan;27(1):8-30
pubmed: 22081500
Neuroimage Clin. 2016 Feb 23;12:e1-e9
pubmed: 27995072
Neuroimage. 2004 Aug;22(4):1732-43
pubmed: 15275929
Mov Disord. 2008 Jan;23(1):42-6
pubmed: 17973326
Mov Disord. 2011 Aug 1;26(9):1633-8
pubmed: 21491489
Transl Neurodegener. 2012 Aug 21;1(1):17
pubmed: 23210661
Neuroimage. 2004 Oct;23(2):724-38
pubmed: 15488422
Neuroimage. 2019 Mar;188:465-472
pubmed: 30578927
Transl Stroke Res. 2020 Aug;11(4):643-652
pubmed: 31677092
Mov Disord. 2020 Mar;35(3):486-494
pubmed: 31758820
Mov Disord. 2019 Apr;34(4):453-459
pubmed: 30759321
Ther Adv Neurol Disord. 2014 Jul;7(4):206-20
pubmed: 25002908
Eur J Neurol. 2012 Feb;19(2):199-206
pubmed: 21762435
Clin Med (Lond). 2016 Aug;16(4):371-5
pubmed: 27481384
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Neurobiol Aging. 2015 Jan;36(1):424-33
pubmed: 25174648
Neuroimage. 2012 Mar;60(1):370-5
pubmed: 22227131
Hum Brain Mapp. 2014 Aug;35(8):3932-44
pubmed: 24453162
Neurology. 2016 Mar 29;86(13):1242-9
pubmed: 26935895
J Neural Transm. 1976;38(3-4):277-301
pubmed: 956814
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
Neuroimage Clin. 2017 Aug 26;16:539-544
pubmed: 29868437
PLoS One. 2016 Apr 01;11(4):e0147947
pubmed: 27035571
Hum Brain Mapp. 2016 Mar;37(3):1148-61
pubmed: 26686837
Neuroimage. 2014 Jul 1;94:40-46
pubmed: 24650599
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
J Parkinsons Dis. 2016 May 27;6(3):557-67
pubmed: 27258697
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Hum Brain Mapp. 2013 Nov;34(11):2798-807
pubmed: 22528144
Acta Radiol. 2015 Jan;56(1):97-104
pubmed: 24413223
Med Phys. 2016 Aug;43(8):4718
pubmed: 27487889
Brain. 2014 Aug;137(Pt 8):2356-67
pubmed: 24951642